NCT06363851View on ClinicalTrials.gov

Single-ascending Dose Study of Kylo-11 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

June 17, 2025

Study Completion Date

December 31, 2025

Conditions

Cardiovascular Diseases

Interventions

DRUG

Kylo-11

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

610000

Chengdu Xinhua Hospital, Chengdu

All Listed Sponsors

lead

Kylonova (Xiamen) Biopharma co., LTD.

INDUSTRY